The FDA approved Suzetrigine in January 2025, the first new class of non-opioid pain drug in 25 years. It works by blocking Nav1.8, a sodium channel found almost exclusively in peripheral pain-sensing nerves. This article by Vandana Mishra traces the full story: why Nav1.8 became a target, how suzetrigine was designed to block it with extraordinary selectivity, what the clinical trials showed, what are the current gaps, and what it means for the future of pain pharmacology.
Nav1.8 and Suzetrigine
How a peripheral sodium channel became the first new class of pain drug in over two decades
What is the problem with current pain drugs?
Pain management has long rested on two pillars: anti-inflammatories like NSAIDs (which reduce peripheral inflammation but have ceiling effects and GI/cardiac risks) and opioids (which are effective but carry addiction risk and CNS side effects). For moderate-to-severe acute pain, opioids have been the default. The US opioid crisis — with over 80,000 overdose deaths in 2023 — made finding a non-addictive alternative urgent.
Why not just block all pain channels?
Voltage-gated sodium channels (Nav channels) drive electrical firing in neurons. There are nine subtypes (Nav1.1–Nav1.9). The problem with older sodium channel blockers like lidocaine or carbamazepine is that they are non-selective — they hit channels in the heart (Nav1.5) and brain (Nav1.1, Nav1.2), causing toxicity and CNS side effects. The goal was to find a channel restricted to pain-sensing neurons and nowhere else.
Nav1.8 — the peripheral pain channel
Nav1.8 is encoded by the gene SCN10A and is almost exclusively expressed in nociceptors — the small, unmyelinated C-fibers and lightly myelinated Aδ-fibers that originate in the dorsal root ganglia (DRG) and detect tissue damage. It is responsible for more than 70% of the depolarizing current during an action potential in these neurons. Critically, Nav1.8 is tetrodotoxin-resistant and essentially absent from the brain and heart — making it a clean, peripheral-specific target.
Human genetic evidence supports this target strongly: gain-of-function mutations in SCN10A cause painful peripheral neuropathy, and loss-of-function variants are associated with reduced pain sensitivity.
Figure 1. Mechanism of action of suzetrigine. Suzetrigine selectively inhibits the Nav1.8 peripheral sodium channel, blocking pain signal initiation at the dorsal root ganglion. (Adapted from Pham A et al. Int. J. Mol. Sci. 2025;26(20):9865. doi: 10.3390/ijms26209865.)
Figure 2. Pharmacology of suzetrigine. Key pharmacokinetic and safety properties at a glance. (Adapted from Pham A et al. Int. J. Mol. Sci. 2025;26(20):9865. doi: 10.3390/ijms26209865.)
How does suzetrigine work?
Nav1.8 is a tetrameric channel with four domains, each containing a voltage-sensing domain (VSD1–VSD4). Suzetrigine binds to VSD2 — a site distinct from the channel pore and from where local anesthetics bind. This is an allosteric mechanism: by stabilizing VSD2 in a position that keeps the channel closed, suzetrigine prevents sodium ion influx without physically plugging the pore.
The result is tonic inhibition — the channel is suppressed even at rest, before any action potential fires. This is unusual. Most channel blockers require the channel to open or inactivate first. Suzetrigine works preemptively.
How selective is it?
Suzetrigine shows over 31,000-fold selectivity for Nav1.8 over every other Nav subtype (Nav1.1–Nav1.7, Nav1.9). Its IC50 for human Nav1.8 is approximately 0.68 nM — extremely potent. In pharmacological panels covering 180 other molecular targets, no significant off-target binding was detected. This is what separates it from earlier, non-selective sodium channel blockers.
The discovery path
Clinical Outcomes: What the Trials Showed
What the trials measured and found
Both pivotal trials (NAVIGATE-1: abdominoplasty, n=303; NAVIGATE-2: bunionectomy, n=274) used SPID48 — Sum of Pain Intensity Differences over 48 hours — as the primary endpoint. Suzetrigine significantly outperformed placebo (SPID48: 29.3–48.4; p<0.0001). Dosing was a 100 mg loading dose followed by 50 mg every 12 hours.
Common adverse effects were itching, muscle spasms, rash, and elevated creatine kinase. No serious cardiac, CNS, or behavioral effects were observed. No organ toxicity signal was detected.
Where the caveats sit
Not superior to opioids: Suzetrigine did not outperform hydrocodone/acetaminophen in pain reduction over 48 hours — it was non-inferior to active comparators, not better. Patients with very high pain needs may still require opioids.
Only two trials: Both were acute surgical models. Efficacy in other pain types (trauma, medical acute pain, cancer pain) is untested at approval.
CYP3A4 interactions: Metabolized by CYP3A4; contraindicated with strong inhibitors (e.g. ketoconazole, ritonavir). Grapefruit must be avoided. This limits use in patients on complex regimens.
Why this approval matters beyond the drug itself
The opioid crisis context matters here. Before suzetrigine, the most recently approved novel analgesic class was celecoxib in 1998. For 25 years, pain pharmacology had no genuinely new mechanism. The approval is a signal that peripheral sodium channel biology is tractable — that selectivity, not just potency, can be the design principle for a pain drug.
The structural biology work using cryo-EM to characterize VSD2 binding was central to getting here. Structure-guided refinement over roughly a decade converted the concept of Nav1.8 inhibition from a proof-of-concept (VX-150) into a clinically viable molecule. This is a textbook example of target-based drug discovery working as intended.
What this opens up
Vertex is currently in Phase III trials for suzetrigine in painful diabetic peripheral neuropathy (DPN), and Phase II data were promising. Lumbosacral radiculopathy is also being evaluated. The broader implication is that if Nav1.8 inhibition works in neuropathic conditions — where treatment options are limited and tolerability matters enormously — the addressable patient population grows substantially.
Other pharmaceutical companies have taken note. Multiple Nav1.8 inhibitor programs are now active globally, and the target is no longer considered speculative.
The core insight: Pain is a peripheral event before it becomes a central one. Nav1.8 sits at the very beginning of that signal — in nociceptors that never reach the brain. By blocking the channel at source, suzetrigine intercepts pain where it starts, not after it has already propagated into the CNS. That is why there is no addiction, no sedation, and no respiratory depression.
What we still do not know
Long-term safety beyond 14 days is unstudied. Whether Nav1.8 blockade affects non-pain peripheral sensory function chronically is not established. Real-world effectiveness in multimodal analgesia settings is being assessed in ongoing Phase IV trials. The drug interaction profile (CYP3A4 and mild CYP3A induction affecting hormonal contraceptives) needs careful clinical attention.
Cost and access are also real barriers — suzetrigine is expected to be substantially more expensive than NSAIDs, and insurance coverage remains variable.
Areas to watch
Key Learnings from the Suzetrigine Story
31,000-fold selectivity for Nav1.8 is what made this safe. Previous broad sodium channel blockers failed because of off-target cardiac and CNS effects.
From VX-150 to suzetrigine, cryo-EM and allosteric binding site characterization were essential. The VSD2 pocket is what made high selectivity achievable.
Both surgical models. Real-world and chronic use data are still needed. The approval was appropriate but the story is not finished.
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org.
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open-source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer-to-peer mentoring and support.
